Safety and feasibility of anlotinib in children with high risk, recurrent or refractory sarcomas: an open-label, single-centre, single-arm, phase Ia/Ib trialResearch in context by Suying Lu, Yi Que, Dongyang Liu, Feifei Sun, Xueting Yao, Liting Deng, Jing Zhan, Junting Huang, Ruiqing Cai, Xin Wang, Shixing Zhu, Zijun Zhen, Jia Zhu, Juan Wang, Yizhuo Zhang

Get full text